Tibet Aim Pharm Inc (002826) - Total Assets
Based on the latest financial reports, Tibet Aim Pharm Inc (002826) holds total assets worth CN¥1.10 Billion CNY (≈ $161.45 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 002826 debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Tibet Aim Pharm Inc - Total Assets Trend (2013–2025)
This chart illustrates how Tibet Aim Pharm Inc's total assets have evolved over time, based on quarterly financial data. See 002826 total equity for net asset value and shareholders' equity analysis.
Tibet Aim Pharm Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Tibet Aim Pharm Inc's total assets of CN¥1.10 Billion consist of 62.3% current assets and 37.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 52.8% |
| Accounts Receivable | CN¥12.74 Million | 1.3% |
| Inventory | CN¥59.78 Million | 5.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥19.20 Million | 1.9% |
| Goodwill | CN¥16.67 Million | 1.6% |
Asset Composition Trend (2013–2025)
This chart illustrates how Tibet Aim Pharm Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Tibet Aim Pharm Inc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tibet Aim Pharm Inc's current assets represent 62.3% of total assets in 2025, an increase from 51.0% in 2013.
- Cash Position: Cash and equivalents constituted 52.8% of total assets in 2025, up from 17.3% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 14.0% in 2013.
- Asset Diversification: The largest asset category is inventory at 5.9% of total assets.
Tibet Aim Pharm Inc Competitors by Total Assets
Key competitors of Tibet Aim Pharm Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Beijing Sun Novo Pharmaceutical Research Co Ltd
SHG:688621
|
China | CN¥2.30 Billion |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
|
China | CN¥8.59 Billion |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111
|
China | CN¥925.41 Million |
|
Jw Pharmac
KO:001060
|
Korea | ₩605.27 Billion |
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Samjin Pharm
KO:005500
|
Korea | ₩449.14 Billion |
Tibet Aim Pharm Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.78 | 2.78 | 3.01 |
| Quick Ratio | 2.56 | 2.63 | 2.73 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥462.81 Million | CN¥379.99 Million | CN¥240.13 Million |
Tibet Aim Pharm Inc - Advanced Valuation Insights
This section examines the relationship between Tibet Aim Pharm Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.36 |
| Latest Market Cap to Assets Ratio | 0.44 |
| Asset Growth Rate (YoY) | 9.8% |
| Total Assets | CN¥1.02 Billion |
| Market Capitalization | $449.78 Million USD |
Valuation Analysis
Below Book Valuation: The market values Tibet Aim Pharm Inc's assets below their book value (0.44x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Tibet Aim Pharm Inc's assets grew by 9.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Tibet Aim Pharm Inc (2013–2025)
The table below shows the annual total assets of Tibet Aim Pharm Inc from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.02 Billion ≈ $148.92 Million |
+9.84% |
| 2024-12-31 | CN¥926.47 Million ≈ $135.57 Million |
-0.14% |
| 2023-12-31 | CN¥927.74 Million ≈ $135.76 Million |
-8.88% |
| 2022-12-31 | CN¥1.02 Billion ≈ $149.00 Million |
+23.50% |
| 2021-12-31 | CN¥824.47 Million ≈ $120.65 Million |
-9.21% |
| 2020-12-31 | CN¥908.09 Million ≈ $132.88 Million |
+8.70% |
| 2019-12-31 | CN¥835.41 Million ≈ $122.25 Million |
+10.22% |
| 2018-12-31 | CN¥757.93 Million ≈ $110.91 Million |
+3.36% |
| 2017-12-31 | CN¥733.29 Million ≈ $107.30 Million |
+13.45% |
| 2016-12-31 | CN¥646.36 Million ≈ $94.58 Million |
+62.53% |
| 2015-12-31 | CN¥397.70 Million ≈ $58.20 Million |
+48.16% |
| 2014-12-31 | CN¥268.42 Million ≈ $39.28 Million |
+75.32% |
| 2013-12-31 | CN¥153.10 Million ≈ $22.40 Million |
-- |
About Tibet Aim Pharm Inc
Tibet AIM Pharm. Inc. engages in the research and development, manufacturing, and sale of medical products in China. The company's products include Miglitol tablets for diabetes; ethnic medicine products, suitable for treating breast lobular hyperplasia, uterine fibroids, and ovarian cysts; gynecology and obstetrics; and NalMefene hydrochloride injection for various acute poisoning, such as alcoh… Read more